Integrated FHIT and IDH2 biomarker profiling predicts lethal sensitivity to DCPS inhibition in Acute Myeloid Leukemia and Myelodysplastic syndrome

Abstract Background/objectives Development of novel therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is hindered by limited biomarkers to identify appropriate target populations and poor translatability of preclinical drug candidates. In this study, we sought to validate...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Francesca Grassi, Lisa Bast, Madhurendra Singh, Magnus Tobiasson, Julian Walfridsson, Angelo de Milito, Martin Andersson, Andreas Höglund
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Springer 2026-03-01
Sarja:	Discover Oncology
Linkit:	https://doi.org/10.1007/s12672-026-04880-x
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!